Hubei Biocause Pharmaceutical Warns of Delisting Risk
Hubei Biocause Pharmaceutical's stock experienced abnormal fluctuations from July 11-15, 2025, with a cumulative closing price deviation exceeding 12%. The company faces potential delisting after failing to disclose its 2024 annual and 2025 first-quarter reports by July 7, 2025. It also received a filing notice from the China Securities Regulatory Commission on May 6, 2025, for alleged non-disclosure. If reports are not disclosed within two months of being under delisting risk warning, trading will be terminated.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
News Alerts
Get instant email alerts when Hubei Biocause Pharmaceutical publishes news
Free account required • Unsubscribe anytime